Chronic Myeloid Leukaemia

Postgraduate Haematology: Fifth Edition

Volumn , Issue , 2007, Pages 603-618

  Goldman, John M ^a   Mughal, Tariq I ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Chronic myeloid leukaemia (CML); Cytogenetics; Cytokinetics; Molecular biology; Staging

Indexed keywords

EID: 84890745936     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987056.ch37     Document Type: Chapter

References (23)

1. Arico M, Biondi A, Pui C-H (1997) Juvenile myelomonocytic leukemia. Blood 90: 479-88.
2. Bain B (2003) Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. British Journal of Haematology 122: 173-9.
3. Barrett AJ (2003) Allogeneic stem cell transplantation for chronic myeloid leukemia. Seminars in Hematology 40: 59-71.
4. Branford S, Rudzki Z, Walsh S et al. (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate binding loop (P-loop) are associated with a poor prognosis. Blood 102: 276-83.
5. Carella AM, Beltrami G, Corsetti MT (2003) Autografting in chronic myeloid leukemia. Seminars in Hematology 40: 72-86.
6. Cools J, DeAngelo DJ, Gotlib J et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine 348: 1201-14.
7. Druker BJ, Talpaz M, Resta DJ et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine 344: 1031-7.
8. Goldman JM (2005) Monitoring minimal residual disease in BCRABL-positive chronic myeloid leukaemia in the imatinib era. Current Opinion in Haematology (in press).
9. Goldman JM, Druker B (2001) Chronic myeloid leukemia: current treatment options. Blood 98: 2039-42.
10. Goldman JM, Melo JV (2003) Chronic myeloid leukemia: advances in biology and new approaches to treatment. New England Journal of Medicine 349: 1449-62.
11. Gratwohl A, Hermans J, Goldman JM et al. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic bone marrow transplantation. Lancet 352: 1087-92.
12. Guilhot F, Chastang C, Michallet M et al. (1977) Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New England Journal of Medicine 337: 223-9.
13. Hasford J, Pfirrmann M, Hehlmann R et al. (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of National Cancer Institute 90: 850-8.
14. Hughes TP, Kaeda J, Branford S et al. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine 349: 1421-30.
15. Melo JV (1996) The molecular biology of chronic myeloid leukaemia. Leukemia 10: 751-6.
16. Mughal TI, Yong A, Szydlo R et al. (2001) The probability of long-term leukaemia free survival for patients in molecular remission 5 years after allogeneic stem cell transplantation for chronic myeloid leukaemia in chronic phase. British Journal of Haematology 115: 569-74.
17. Niemeyer CM, Fenu S, Hasle H et al. (1998) Differentiating juvenile myelomonocytic leukemia from infectious disease -response. Blood 91: 366-7.
18. O'Brien SG, Guilhot F, Larson RA et al. (2003) Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine 348: 994-1004.
19. Sawyers CL (1999) Chronic myeloid leukemia. New England Journal of Medicine 340: 1330-40.
20. Shah NP, Nicholl JM, Nagar B et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STIS71) in chronic phase and blastic crisis chronic myeloid leukemia. Cancer 2: 117-25.
21. Shannon KM (2002) Resistance in the land of molecular therapeutics. Cancer Cell 2: 99-102.
22. Sokal JE, Cox EB, Baccarani M et al. (1984) Prognostic discrimination in 'good risk' chronic granulocytic leukemia. Blood 63: 789-99.
23. World Health Organization (2001) World Health Organization Classification of Tumours. Tumours of the Haemopoietic and Lymphoid Tissues (ES Jaffe, NL Harris, H Stein et al., eds), pp. 20-6. IARC Press, Lyon.